On May 15, the "2023 China Healthcare and Health Industry Investment and Financing Honor List" is officially announced. ArkBio, with its outstanding innovation capabilities and ever-growing industry influence, was honored as one of the "Top 50 Most Influential Healthcare Companies of 2023."

About ArkBio·

ArkBio is a global biotech company focusing on discovery and development of innovative drugs for unmet medical needs, especially in the therapeutic areas of respiratory, infectious and pediatric diseases. Since its inception in 2014, the company has established core technology platforms and built an innovative and highly differentiated R&D pipeline through in-house R&D efforts and external collaborations. This strong R&D pipeline program includes innovative clinical and pre-clinical stage drug candidates with first- or best-in-class potential for global clinical development. As one of the core assets, ziresovir is the first direct-acting RSV antiviral drug that has been developed by ArkBio. 

ArkBio has established strategic partnerships with several global pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture investment institutions. 

For more information about the company, please visit our website: www.arkbiosciences.com

Investor Inquiries：IR@arkbiosciences.com

About the "China Healthcare and Health Industry Investment and Financing Honor List"

The "Annual China Healthcare and Health Industry Investment and Financing Honor List" is jointly launched by CHC Healthcare Consulting and CITIC Securities. It is an authoritative list from a third-party perspective in the healthcare and health field. The list aims to recognize those who have made significant contributions to the Chinese healthcare and health industry, establishing a benchmark for the industry to "respect value, embrace value, and create value." The list is selected based on a comprehensive assessment of the current investment and financing status in the healthcare industry, as well as corporate financing, development, and valuation metrics. Since the first release in 2018, the Honor List has become an important indicator of the development and investment trends in China's healthcare sector. The release of the list not only honors the contributors to the healthcare industry but also encourages and motivates the entire industry, reflecting the positive values and energy within the sector.